objective to evaluate the efficacy and safety of acetaminophen 1000 mg for the treatment of episodic migraine headachebackground while acetaminophen is commonly used to treat migraine there have been limited published clinical trial efficacy resultsdesignmethods ten investigators at 13 private ambulatory primary care sites in the united states enrolled and treated 346 outpatient adults 1872 years of age with migraine headache of moderate to severe intensity into a randomized placebocontrolled doubleblind clinical trial of 6 hours durationeach patient was randomly assigned to a single dose of study medication of acetaminophen 1000 mg n  177 or placebo n  169the percentage of patients with a reduction in baseline headache pain intensity from severe or moderate to mild or none 2 hours after treatment and the headache pain intensity difference from baseline at 2 hours were the primary efficacy measuresother measures of pain relief severity differences from baseline for migraineassociated symptoms of nausea photophobia phonophobia and functional disability and percentage of patients with migraineassociated symptoms reduced to none were also assessedresults significantly p  001 more patients treated with acetaminophen 1000 mg reported mild to no pain after 2 hours 520 compared with those treated with placebo 320the mean pain intensity difference from baseline measured at 2 hours was significantly p  001 greater for patients treated with acetaminophen 1000 mg 082 compared with those treated with placebo 046a significant difference in favor of acetaminophen 1000 mg over placebo was also observed at 1 hour after treatment for the percentage of patients with mild to no pain and for mean pain intensity difference from baselineacetaminophen 1000 mg was significantly more effective than placebo for all but 1 pain reduced to none at 2 hours clinically important secondary pain relief outcomesmean severity changes from baseline in migraineassociated symptoms of nausea photophobia phonophobia and functional disability at 2 and 6 hours were significantly p  001 in favor of acetaminophen over placebo the percentage of patients with no symptoms at 2 and 6 hours statistically significantly favored acetaminophen in 6 of 8 comparisonsadverse events overall and specifically for nausea were reported more frequently in the placebo groupconclusions acetaminophen 1000 mg a nonprescription drug is an effective and welltolerated treatment for episodic and moderate migraine headachein addition acetaminophen generally provided a beneficial effect on associated symptoms of migraine including nausea photophobia phonophobia and functional disability